| Brett R Lindau, DO | |
|
145 Memorial Drive, Broken Bow, NE 68822 | |
| (308) 872-2486 | |
| (308) 872-2938 |
| Full Name | Brett R Lindau |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 145 Memorial Drive, Broken Bow, Nebraska |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114153384 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DR.0049425 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jennie M Melham Memorial Medical Center | Broken bow, NE | Hospital |
| Brookestone View | Broken bow, NE | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Nebraska Medical Clinic Pc | 4486640265 | 9 |
| Jennie M Melham Memorial Medical Center Inc | 5799766440 | 8 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
As SciDev.Net celebrates 20 years of reporting about the impact of science on people in low- and middle-income countries, the need for our work is greater than ever.
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
› Verified 1 days ago
| Entity Name | Central Nebraska Medical Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578668232 PECOS PAC ID: 4486640265 Enrollment ID: O20040426000695 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
As SciDev.Net celebrates 20 years of reporting about the impact of science on people in low- and middle-income countries, the need for our work is greater than ever.
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
› Verified 1 days ago
| Entity Name | Jennie M Melham Memorial Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366659773 PECOS PAC ID: 5799766440 Enrollment ID: O20040527000928 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
As SciDev.Net celebrates 20 years of reporting about the impact of science on people in low- and middle-income countries, the need for our work is greater than ever.
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
› Verified 1 days ago
| Entity Name | Jennie M Melham Memorial Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538232244 PECOS PAC ID: 5799766440 Enrollment ID: O20071129000446 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
As SciDev.Net celebrates 20 years of reporting about the impact of science on people in low- and middle-income countries, the need for our work is greater than ever.
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett R Lindau, DO Po Box 690, Broken Bow, NE 68822 Ph: (308) 872-2486 | Brett R Lindau, DO 145 Memorial Drive, Broken Bow, NE 68822 Ph: (308) 872-2486 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
As SciDev.Net celebrates 20 years of reporting about the impact of science on people in low- and middle-income countries, the need for our work is greater than ever.
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.
› Verified 1 days ago
Mrs. Katrina A White, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Memorial Drive, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 | |
Mrs. Shawn S Lawrence, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 805 South F Street, Broken Bow, NE 68822 Phone: 308-872-6456 Fax: 308-872-6040 | |
Dr. Norval Leon Books, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1245 North 11th Ave, Broken Bow, NE 68822 Phone: 308-872-6244 | |
Mrs. Melinda S Barratt, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 805 South F Street, Broken Bow, NE 68822 Phone: 308-872-6456 Fax: 308-872-6040 | |
Katie Thompson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Memorial Dr, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 | |
Dr. Robert R Kahnk, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 145 Memorial Dr, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 |